SORT BY Relevancy
The Neurophone as invented by Dr. G. Patrick Flanagan of www.phisciences.com (at age 13) is able to convert ANY sound through the input jack built in the device into ultrasonic sound that is picked up by our inner ear, our saccules, and the information/sound goes straight into your BRAIN. Normally when we hear stuff the sound gets translated into information that we process in our minds but through the use of this accelerated learning device, you can PUT INFORMATION DIRECTLY INTO LONG TERM STORAGE WITH EASE! The Neurophone balances left and right brain hemispheres, and using it for one hour successfully puts you in an Alpha state of consciousness, an ideal state for learning new information. (This is a truth seekers best friend) Patrick says just having it on increases your ability to learn and process information, and that on IQ tests your IQ is boosted. There is actually much more this device is capable of and it's very fascinating, but sinister as well! You can't just simply believe this technology would be allowed on the market if there wasn't some more evil reason behind it....unless you're really that trusting of a person. Patrick has worked for and has been affiliated with many think tanks and organizations including the Navy/Office of Naval Research, DOD/Pentagon, CIA, NASA, Aberdeen Proving Grounds for the Department of Unconventional Weapons and Warfare, among other orgs
With the NEO (Neural Efficiency Optimizer) Neurophone set to hit the market in June 2015 for the low low price of $399 , could there be more to this techno-meditation device? Perhaps a more evil plan to "update" all current NF3 Neurophone users (who have been training their inner ears) onto the NEO, and perhaps be able to successfully use Blue Beam sound/holographic technology against them??? NASA is definitely involved. Tonight I have compiled a ton of REVERSALS (reverse speech) on the matter.
Could multiple myeloma genetics give us clues into who will respond to standard treatments and who will not? Dr. Brian Van Ness, PhD of the University of Minnestota shares his study to do just that. In a collaboration between the Unversity of Minnesota and the Mayo Clinic, Dr. Van Ness will describe his study to determine who will respond to treatment (or not) even before the treatment is given. Learn more about how standard therapies can be effectively used in this important show.
Myeloma is not a single disease. Two types of high-risk myeloma have swapped chromosomes (14;16) and (14;20) have notoriously short survival times with conventional treatments and are found to be resistant to bortezomib, one of the standard myeloma therapies. Dr. Frank Zhan, MD, PhD of the University of Iowa searched a genetic database to identify 100 genes uniquely deregulated for these two types of myeloma. Based on database matching to find compounds that induce or reverse desired gene changes, he found 5 targets to affect the c-MAF and MAFB genes that are disregulated by these translocations. They found that only Alsterpaullon (ALP) significantly inhibits MM cell growth with “spike” expression of either c-MAF or MAFB. ALP is a cyclindependent kinase (CDK) inhibitor and blocks cell-cycle progression. However, the reasons for its antiproliferative effects is unknown. The research will test whether ALP is able to disable c-MAF/MAFB signaling events, thus rendering MM responsive to chemotherapeutics.
Join us for this 6th show of the Myeloma Crowd Research Initiative with Dr. Frank Zhan, MD, PhD and Dr. Guido Tricot, MD, PhD to discuss a potential solution for these patients in a truly personalized medicine fashion.
Dr. Ivan Borrello, MD of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, joins us as part of the top 10 projects selected by the Myeloma Crowd Research Initiative. He shares his pioneering work using patients' own immune cells to fight their cancer. His group leads the research for this type of immunotherapy, called adaptive T-cell therapy with MILS (marrow infiltrating lymphocytes). This vaccine is a version for multiple myeloma of those already successful to treat pancreas, prostate and breast cancers. Learn more about this important work in his upcoming study in multiple myeloma.
The measles virus used successfully for a patient with relapsed myeloma is now a well known and exciting story shared on maintstream media. Dr. Frits van Rhee MD PhD MRCP, FRCPath and Dr. Stephen Russell, MD PhD FRCP, FRCPath take the success one step further with a Phase II trial of the measles virus with further engineering in patients with relapsed/refractory, high-risk multiple myeloma. Their work will help determine which patients will respond to the treatment and which ones will not and will also determine how to make the therapy more effective.
Join us for our second interview on Myeloma Crowd Radio highlighting the new Myeloma Crowd Research Initiative on high-risk myeloma. As part of this series, Dr. Guenther Koehne, MD, PhD of the Memorial Sloan Kettering Cancer Center will share his use of a T cell vaccine with an allogeneic transplant to provide outstanding results, even in plasma leukemia patients. His research pulls out T cells, marks them with a tag to target the WT1 protein, and are given back. He will describe how this works, the impact he has seen so far, the stage of his clinical trial and the work left to do to make this an available therapy for high-risk myeloma patients.
Dr. Guenther Kohene, MD, PhD is Medical Director of the Cell Therapy Laboratory in the Bone Marrow Transplantation Laboratory at Sloan Kettering. He is also Assistant Member and Assistant Attending Physician in the Allogeneic Bone Marrow Transplantation Service. He is Assistant Professor of the Joan and Sanford Weill Medical College of Cornell University. He leads research at the BMT Department/Immunology Program to develop adoptive immunotherapeutic strategies for post-transplant blood disorders. He has particular expertise in the creation and monitoring of antigen-specific T cell responses in these patients. He is the Principal Investigator in active clinical trials using adoptive cell therapy following allogeneic stem cell transplants for multiple myeloma and plasma cell leukemia patients. He obtained his medical degree at the University of Hamburg, Germany and has been at Memorial Sloan Kettering Cancer Center permanently since 2005.
Special thanks to our Myeloma Crowd Radio Episode sponsor, Takeda Oncology.
UAMS has led the way in studying the biology of myeloma cells to find new therapies. We now know that multiple myeloma patients can have a variety of types of myeloma cells at the time they are diagnosed - some with more aggressive features than others. Researchers have found that patients with several different types of myeloma cells at diagnosis seem to have early relapse and shorter survival while patients with one dominant type of myeloma cell tend to do better. Learn what Dr. Gareth Morgan, MD, FRCP, FRCPath, PhD, Dr. Niels Weinhold, PhD and Dr. Christoph Hueck are doing to find out which clones are the most aggressive and which therapies increase the mutation rate, leading to a more resistant myeloma clone.
Join us as we wrap up this term's subject, Physical Dimensions of Free-Choice Learning. Joining us will be guest Dr. Laura Good, of the Stanford Center for Ocean Solutions, who worked for several years in YMCA camps. She'll share her experiences there and how the physical setting affected learning opportunities. She will also talk about where her free-choice learning work has taken her in terms of her current position.
Patients who have high-risk genetic features like the 14;16 translocation need new treatment options. Dr. Carmen Baldino of Jasco Pharmaceuticals and Dr. Kelvin Lee of the Roswell Park Cancer Institute are working on a potentially curative solution for patients with this high-risk translocation using a PIM2 Kinase inhibitor called JP-11646. Learn more about this proposal for the Myeloma Crowd Research Initiative to address the unmet needs for high-risk patients.
Join us for this first interview on Myeloma Crowd Radio highlighting new Myeloma Crowd Research Initiative on high-risk myeloma. For the first time, patients and doctors are joining together to find and fund research for patient group that is desperate for new options. The MCRI initiative reached out the the worldwide community and asked them to submit their research proposals for high-risk patients. We received 36 high quality proposals from all over the world. The MCRI Scientific Advisory Board then scored the proposals, selecting 10 for further review. These ten will be included in the Myeloma Crowd Radio/MCRI series on high-risk.
As part of this series, Dr. Craig Hofmeister, MD from Ohio State University will share his research being done to use engineered CAR T cells to specifically target the high-risk types of multiple myeloma.
Thanks to our episode sponsor, Takeda Oncology.
CAR T cell therapy is a new and exciting potential treatment approach in blood cancers. It is a highly personalized treatment because the patient's own T-cells are redirected to erradicate cancerous cells after a single infusion, allowing patients to avoid the chronic side effects of long-term, toxic chemoradiotherapy. Learn more about Dr. Hermann Einsele, MD and Dr. Michael Huedecek, MD's work at the University of Würzburg, Germany to use a CAR T cell therapy targeting the CS1 protein commonly found on myeloma cells.
Join Host Live Chats
- Talk Real Solutions (46 chatters)
- Pro Wrestling Torch (22 chatters)
- Curious Times (12 chatters)
- Fresh Fire Prayer LineBrother Kay (10 chatters)
- Mega Powers Radio (8 chatters)
- RampageRadio (5 chatters)
- Vinny Bond (5 chatters)
- Jay King Network (4 chatters)
- The Hilltop Radio Show (3 chatters)
- THEE ALMIGHTY ALLSUNDARA (2 chatters)
- Vibration Radio (2 chatters)
- Real1Talk1 (2 chatters)
- WMLR- MOOR LIFE RADIO (2 chatters)
- ROADTOSTARDOM RADIO (1 chatters)
- IMTM Worldwide Radio (1 chatters)
- Fellowship of Deliverance (1 chatters)
- FreedomizerRadio (1 chatters)
- New Hope Radio (1 chatters)
- nwo truth radio media (1 chatters)
- Top Star Hip Hop Radio (1 chatters)